G.ST Antivirals
G.ST Antivirals applies an innovative host cell-based strategy to develop broad-spectrum antivirals against infections of the respiratory tract.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | €2.0m | Grant | |
| Total Funding | 000k | ||
Related Content
G.ST Antivirals is a biotechnology startup based in Vienna, Austria, spun off from the Medical University of Vienna. The company focuses on developing innovative therapies to combat various viral infections. Unlike traditional antiviral treatments, G.ST Antivirals employs a novel approach that targets the virus in a unique way, potentially offering more effective solutions.
The company primarily serves the healthcare sector, including hospitals, clinics, and pharmaceutical companies that are in need of advanced antiviral treatments. Their market is global, given the universal need for effective antiviral therapies, especially in light of recent global health crises.
G.ST Antivirals operates on a business-to-business (B2B) model. They develop and patent their antiviral therapies and then license these patents to pharmaceutical companies. This licensing model allows them to generate revenue without the need for large-scale manufacturing and distribution operations. Additionally, they may engage in partnerships or collaborations with other biotech firms and research institutions to further their research and development efforts.
The leadership team at G.ST Antivirals is highly experienced and well-credentialed. Guido Gualdoni, the CEO and Co-Founder, holds both an MD and a PhD in Immunology and has made significant discoveries in the field, including the potential of 2-deoxyglucose against rhinovirus infections. Johannes, another Co-Founder, also holds a PhD in Immunology and brings over 20 years of experience in immunology and rhinovirus research. Anna Dorothea Gorki, the Chief Scientific Officer, is an expert in respiratory tract infections and has an impressive background in molecular medicine.
In summary, G.ST Antivirals is a promising player in the biotech industry, leveraging cutting-edge research to develop new antiviral therapies. Their innovative approach and experienced team position them well for future growth and success.
Keywords: biotechnology, antiviral therapies, immunology, rhinovirus, healthcare, B2B, licensing, research, innovation, Vienna.